Immune Cell Engineering For Targeted Therapy And Disease Monitoring in Type 1 Diabetes (R01 Clinical Trial Not Allowed)

Funding Opportunity RFA-DK-21-005 from the NIH Guide for Grants and Contracts. This initiative will support the engineering of immune cells to target the human pancreatic compartment to report on previously inaccessible information about diabetes initiation and progression, and to deliver environment-specific therapeutic responses to restore islet health and prevent the progression to T1D.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding